Cytokinetics to Announce First Quarter Results on April 30, 2015
April 16 2015 - 4:00PM
South San Francisco, CA., April 16, 2015, -
Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it
is scheduled to report first quarter results on Thursday, April 30,
2015 at 4:00 PM Eastern Time. Following the announcement,
Cytokinetics' senior management will host a conference call at 4:30
PM Eastern Time to discuss operational and financial results and
the company's outlook for the future.
The conference call will be
simultaneously webcast and can be accessed from the homepage and in
the Investor Relations section of Cytokinetics' website at
www.cytokinetics.com. The live audio of the conference call can
also be accessed by telephone by dialing either (866) 999-CYTK
(2985) (United States and Canada) or (706) 679-3078 (international)
and typing in the passcode 34463154.
An archived replay of the webcast
will be available via Cytokinetics' website until April 30,
2015. The replay will also be available via telephone by
dialing (855) 859-2056 (United States and Canada) or (404) 537-3406
(international) and typing in the passcode 34463154 from April
30, 2015 at 5:30 PM Eastern Time until May 7, 2015.
About
Cytokinetics
Cytokinetics is a clinical-stage
biopharmaceutical company focused on the discovery and development
of novel small molecule therapeutics that modulate muscle function
for the potential treatment of serious diseases and medical
conditions. Cytokinetics is developing tirasemtiv, a fast skeletal muscle activator, as a
potential treatment for amyotrophic lateral sclerosis (ALS).
Tirasemtiv has been granted orphan drug
designation and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by the
European Medicines Agency for the potential treatment of ALS.
Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a cardiac muscle activator, for the
potential treatment of heart failure. Cytokinetics is collaborating
with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal
muscle activator, for the potential treatment of spinal muscular
atrophy. Amgen holds an exclusive license worldwide to develop and
commercialize omecamtiv mecarbil and Astellas
holds an exclusive license worldwide to develop and commercialize
CK-2127107. Both licenses are subject to Cytokinetics' specified
development and commercialization participation rights. All of
these drug candidates have arisen from Cytokinetics' muscle biology
focused research activities and are directed towards the
cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human
cell. Additional information about Cytokinetics can be obtained at
http://www.cytokinetics.com/.
This press
release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act").
Cytokinetics disclaims any intent or obligation to update these
forward-looking statements, and claims the protection of the Act's
safe harbor for forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
planned presentations, and the properties and potential benefits of
Cytokinetics' drug candidates and potential drug candidates, as
well as statements relating to Cytokinetics'
and its partners' research and development activities. Such statements are based on management's current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to,
potential difficulties or delays in the development, testing,
regulatory approval and production of Cytokinetics' drug candidates
and potential drug candidates that could slow or prevent clinical
development or product approval, including risks that current and
past results of clinical trials or preclinical studies may not be
indicative of future clinical trials results and that Cytokinetics'
drug candidates and potential drug candidates may have unexpected
adverse side effects or inadequate therapeutic efficacy. For
further information regarding these and other risks related to
Cytokinetics' business, investors should consult Cytokinetics'
filings with the Securities and Exchange Commission.
Contact:
Joanna L.
Goldstein
Manager, Investor Relations & Corporate
Communications
(650) 624-3000
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Cytokinetics, Inc. via Globenewswire
HUG#1911954
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024